subscribeSubscribe
US FDA approves expanded use of BeiGene`s blood cancer drug

US FDA approves expanded use of BeiGene`s blood cancer drug
Mariam E Sunny REUTERS
08 Mar 2024
Share Share
Nektar and Collaborators Present Data on NKTR-255 in Presentation

Nektar and Collaborators Present Data on NKTR-255 in Presentation
PR NEWSWIRE
11 Dec 2023
Share Share
Roche withdraws EMA expansion application for cancer medicine Gazyvaro

Roche withdraws EMA expansion application for cancer medicine Gazyvaro
Katherine Lewin ENDPTS
21 Jul 2023
Share Share
Long-Term ROSEWOOD Data Confirm Efficacy of Zanubrutinib Plus

Long-Term ROSEWOOD Data Confirm Efficacy of Zanubrutinib Plus
Courtney Flaherty ONCOLIVE
27 Jun 2023
Share Share
Venetoclax/Atezolizumab/Obinutuzumab Elicits Durable Responses in Richter

Venetoclax/Atezolizumab/Obinutuzumab Elicits Durable Responses in Richter
Ryan Scott ONCOLIVE
23 Jun 2023
Share Share
Venetoclax Plus Obinutuzumab Demonstrates Durable Survival Benefit

Venetoclax Plus Obinutuzumab Demonstrates Durable Survival Benefit
PRESS RELAESE
22 Jun 2023
Share Share
Ibrutinib, Obinutuzumab, Venetoclax Triplet Elicits Clinical Benefit in MCL

Ibrutinib, Obinutuzumab, Venetoclax Triplet Elicits Clinical Benefit in MCL
Ryan Scott ONCLIVE
19 Jun 2023
Share Share
Chugai Pharma’s Gazyva gets Japanese MHLW approval for an additional indication

Chugai Pharma’s Gazyva gets Japanese MHLW approval for an additional indication
PHARMABIZ
24 Dec 2022
Share Share
Genentech`s Gazyva (obinutuzumab) Receives BLA Approval in the U.S.

Genentech`s Gazyva (obinutuzumab) Receives BLA Approval in the U.S.
FDA
27 Jul 2022
Share Share
Genentech`s Gazyva (obinutuzumab) Receives Supplemental Approval in U.S.

Genentech`s Gazyva (obinutuzumab) Receives Supplemental Approval in U.S.
FDA
12 Jul 2022
Share Share